MERISLON TABLET 6mg

Product Information

Registration Status: Active

MERISLON TABLET 6mg is approved to be sold in Singapore with effective from 1989-07-06. It is marketed by EISAI (SINGAPORE) PTE LTD, with the registration number of SIN03047P.

This product contains Betahistine 6mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by EISAI CO LTD in JAPAN.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Betahistine

Description

Betahistine is an antivertigo drug first used for treating vertigo assosicated with Ménière's disease. It is also commonly used for patients with balance disorders.

Indication

For the reduction of episodes of vertigo association with Ménière's disease.

Pharmacokinetics

Absorption
When given orally, betahistine is rapidly absorbed from the gastrointestinal tract.
Distribution
Metabolism
Betahistine is metabolized primarily into 2-pyridylacetic acid and is subsequently excreted in the urine.
Elimination

Toxicity

Symptoms of overdose (< 640 mg) include mild to moderate nausea, dry mouth, dyspepsia, abdominal pain and somnolence. More serious complications such as convulsions, pulmonary or cardiac complications, may occur with higher intentional overdoses (> 640 mg).

Active Ingredient/Synonyms

[2-(2-Pyridyl)ethyl]methylamine | 2-(beta-Methylaminoethyl)pyridine | 2-[2-(Methylamino)ethyl]pyridine | Betahistina | Betahistinum | N-Methyl-2-(2-pyridinyl)ethanamine | N-Methyl-2-pyridineethanamine | Betahistine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank